CPT Pharmacometrics & Systems Pharmacology · 2020 · 17 citations · 27 references
PharmacyPharmacokineticsPharmacologyAntibody EngineeringDrug DiscoveryPharmacokinetic ModelingAntibody CharacterizationAntibody DiscoveryAntibody PharmacokineticsPharmacokinetics Of Monoclonal AntibodiesTherapeutic Antibody DevelopmentTherapeutic Monoclonal AntibodiesDruggable Target DiscoveryEarly Drug DiscoveryFc Neonatal Receptor BindingFcrn-mediated RecyclingNeonatal Fc Receptor BindingNeonatal Fc Receptor RecyclingTarget CoverageTarget Coverage Evaluation
Monoclonal antibodies (mAbs) can be engineered to have "extended half-life" and "catch and release" properties to improve target coverage. We have developed a mAb physiologically-based pharmacokinetic model that describes intracellular trafficking, neonatal Fc receptor (FcRn) recycling, and nonspecific clearance of mAbs. We extended this model to capture target binding as a function of target affinity, expression, and turnover. For mAbs engineered to have an extended half-life, the model was able to accurately predict the terminal half-life (82% within 2-fold error of the observed value) in the human FcRn transgenic (Tg32) homozygous mouse and human. The model also accurately captures the trend in pharmacokinetic and target coverage data for a set of mAbs with differing catch and release properties in the Tg32 mouse. The mechanistic nature of this model allows us to explore different engineering techniques early in drug discovery, potentially expanding the number of "druggable" targets.
27
Enhanced neonatal Fc receptor function improves protection against primate SHIV infection
Sung‐Youl Ko, Amarendra Pegu, Rebecca S. Rudicell et al. · Nature · 2014 · 400 citations
Gabriel J. Robbie, Ryan Criste, William F. Dall’Acqua et al. · Antimicrobial Agents and Chemotherapy · 2013 · 353 citations · Full text